While Arrow's shares have risen 52 percent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves. "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst Andrew Williams said, adding Arrow's potential reserves support a valuation of A$5.5O a share. 
Share:  While <span class="company">Arrow</span>'s shares have risen 52 percent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves.<span class="sent"> "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of A$5.5O a share.</span>...While <span class="company">Arrow</span>'s shares have risen 52 percent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves.<span class="sent"> "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of A$5.5O a share.</span>...<span class="sent">"We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of A$5.5O a share.</span> Earlier this week, a source told Reuters that <span Tweet this 

While Arrow's shares have risen 52 percent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves. "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst Andrew Williams said, adding Arrow's potential reserves support a valuation of A$5.5O a share. 
Share:  While <span class="company">Arrow</span>'s shares have risen 52 percent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves.<span class="sent"> "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of A$5.5O a share.</span>...While <span class="company">Arrow</span>'s shares have risen 52 percent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves.<span class="sent"> "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of A$5.5O a share.</span>...<span class="sent">"We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of A$5.5O a share.</span> Earlier this week, a source told Reuters that <span class="company">Arrow</span> had opened its books to Shell and PetroChina, and would Tweet this 

"Liberalization is key to our outperform stance on EDF," Elisenne Verdoja, a London based analyst at Credit Suisse, wrote in a note to clients. 
Share:  <span class="sent">"Liberalization is key to our outperform stance on EDF," Elisenne Verdoja, a London based analyst at Credit Suisse, wrote in a note to clients.</span> Tweet this 

While Arrow's shares have risen 52 per cent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves. "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst Andrew Williams said, adding Arrow's potential reserves support a valuation of $5.5O a share. 
Share:  While <span class="company">Arrow</span>'s shares have risen 52 per cent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves.<span class="sent"> "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of $5.5O a share.</span>...While <span class="company">Arrow</span>'s shares have risen 52 per cent to a record since the deal was first announced, analysts believe the current offer price is low given the potential reserves.<span class="sent"> "We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of $5.5O a share.</span>...<span class="sent">"We believe the offer will succeed or fail on the cash component for local investors ..and $4.45 a share appears too low," Credit Suisse analyst <span class="analyst">Andrew Williams</span> said, adding <span class="company">Arrow</span>'s potential reserves support a valuation of $5.5O a share.</span> Earlier this week, a source told Reuters that <span class="company">Arrow</span> had opened its books to Shell and PetroChina, and Tweet this 

Analysts at Credit Suisse have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No 2, Novartis's Sandoz unit, at about 11 percent. 
Share:  <span class="sent">Analysts at <span class="analyst">Credit Suisse</span> have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No 2, <span class="company">Novartis</span>'s Sandoz unit, at about 11 percent.</span> Tweet this 

Analysts at Credit Suisse have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No 2, Novartis's Sandoz unit, at about 11 percent. 
Share:  <span class="sent">Analysts at <span class="analyst">Credit Suisse</span> have said a takeover would move <span class="company">Teva</span>'s global generics market share to around 19 percent, widening the gap over No 2, Novartis's Sandoz unit, at about 11 percent.</span> Tweet this 

According to Credit Suisse analyst Glen Santangelo, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%. Adding opportunity for generic drugmakers like Teva, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of Teva traded on the Nasdaq exchange gained $2.33, or 3.9%, to $62.27 Thursday 
Share:  <span class="sent">According to Credit Suisse analyst <span class="analyst">Glen Santangelo</span>, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%.</span> Adding opportunity for generic drugmakers like <span class="company">Teva</span>, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of <span class="company">Teva</span> traded on the Nasdaq exchange gained $2.33, or 3.9%, to $62.27 Thursday....<span class="sent">According to Credit Suisse analyst <span class="analyst">Glen Santangelo</span>, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%.</span> Adding opportunity for generic drugmakers like <span class="company">Teva</span>, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of <span class="company">Teva</span> traded on the Nasdaq exchange gained $2.33, or 3.9%, to $62.27 Thursday. Tweet this 

According to Credit Suisse analyst Glen Santangelo, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%. Adding opportunity for generic drugmakers like Teva, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of Teva traded on the Nasdaq exchange gained $1.82, or 3%, to $61.76 Thursday 
Share:  <span class="sent">According to Credit Suisse analyst <span class="analyst">Glen Santangelo</span>, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%.</span> Adding opportunity for generic drugmakers like <span class="company">Teva</span>, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of <span class="company">Teva</span> traded on the Nasdaq exchange gained $1.82, or 3%, to $61.76 Thursday....<span class="sent">According to Credit Suisse analyst <span class="analyst">Glen Santangelo</span>, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%.</span> Adding opportunity for generic drugmakers like <span class="company">Teva</span>, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of <span class="company">Teva</span> traded on the Nasdaq exchange gained $1.82, or 3%, to $61.76 Thursday. Tweet this 

Shares of NKE are up 6.00% to fresh all time highs with help from analysts at both FBR and Credit Suisse which raised price targets to $84 , $85 with catalysts such as a V shaped recovery in China, accelerating future orders and the World Cup this summer acting as support for Nike shares to move higher. 
Share:  <span class="sent">Shares of NKE are up 6.00% to fresh all time highs with help from analysts at both FBR and <span class="analyst">Credit Suisse</span> which raised price targets to $84 , $85 with catalysts such as a V shaped recovery in China, accelerating future orders and the World Cup this summer acting as support for Nike shares to move higher.</span> Tweet this 

Analysts at Credit Suisse have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No. 2, Novartis's Sandoz unit, at about 11 percent. 
Share:  <span class="sent">Analysts at <span class="analyst">Credit Suisse</span> have said a takeover would move <span class="company">Teva</span>'s global generics market share to around 19 percent, widening the gap over No. 2, Novartis's Sandoz unit, at about 11 percent.</span> Tweet this